Gene:
PRKCB
protein kinase C, beta

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for PRKCB

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs11649514 NC_000016.10:g.24175240G>T, NC_000016.9:g.24186561G>T, NG_029003.1:g.344262G>T, NM_002738.6:c.1394+660G>T, NM_212535.2:c.1394+660G>T, rs17814396, rs59690611
G > T
SNP
No VIP available CA VA
rs9922316 NC_000016.10:g.23898631T>G, NC_000016.9:g.23909952T>G, NG_029003.1:g.67653T>G, NM_002738.6:c.205+61225T>G, NM_212535.2:c.205+61225T>G, rs12919963, rs58552219
T > G
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  PKCB; PRKCB1; PRKCB2
Alternate Symbols:  None
PharmGKB Accession Id: PA33761

Details

Cytogenetic Location: chr16 : p12.2 - p12.1
GP mRNA Boundary: chr16 : 23847300 - 24231932
GP Gene Boundary: chr16 : 23837300 - 24234932
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Beta-agonist/Beta-blocker Pathway, Pharmacodynamics
    Simplified pharmacodynamic pathway of drug action on beta 2 adrenergic receptor in a stylized airway cell.
  1. EGFR Inhibitor Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes that may be involved in the treatment using epidermal growth factor receptor specific tyrosine kinase inhibitors or monoclonal antibodies.
  1. Proton Pump Inhibitor Pathway, Pharmacodynamics
    Genes involved in the proton pump activation and trafficking.
  1. VEGF Signaling Pathway
    Model endothelial cell displaying genes of the VEGF signalling pathway and the sites at which bevacizumab, sorafenib, sunitinib, brivanib and cilengitide are known to act.

Curated Information ?

Curated Information ?

Curated Information ?

Publications related to PRKCB: 8

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation?. Clinical and translational science. 2016. Chang S W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A polymorphism in the protein kinase C gene PRKCB is associated with alpha2-adrenoceptor-mediated vasoconstriction. Pharmacogenetics and genomics. 2013. Posti Jussi P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-beta. The pharmacogenomics journal. 2010. Pavan C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Parathyroid hormone: past and present. The Journal of endocrinology. 2005. Potts John T. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003. Ross Mary E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1. Cancer chemotherapy and pharmacology. 2003. Ali Shadan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer cell. 2002. Yeoh Eng-Juh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999. Takahashi T, et al. PubMed

LinkOuts

NCBI Gene:
5579
OMIM:
176970
UCSC Genome Browser:
NM_002738
RefSeq RNA:
NM_002738
NM_212535
RefSeq Protein:
NP_002729
NP_997700
RefSeq DNA:
NT_010393
UniProtKB:
KPCB_HUMAN (P05771)
Ensembl:
ENSG00000166501
GenAtlas:
PRKCB1
GeneCard:
PRKCB
PRKCB1
MutDB:
PRKCB1
ALFRED:
LO019438Z
HuGE:
PRKCB1
ModBase:
Q9UJ30
HumanCyc Gene:
HS09408
HGNC:
9395

Common Searches